Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer

This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with refractory metastatic colorectal cancer. Clinical data from patients diagnosed with colorectal cancer will be collected and analyzed in this study. The patients’ data will be collected and maintained in the Division of medical oncology of the Department of Medicine, Queen Mary Hospital.

本研究为一项开放标签、单中心、单臂II期临床试验，旨在评估卡培他滨（capecitabine）、奥沙利铂（oxaliplatin）与伊立替康（irinotecan）三联联合方案（Xeloxiri方案）治疗难治性转移性结直肠癌患者的疗效与耐受性。本研究将收集并分析结直肠癌确诊患者的临床数据，相关患者数据将由玛丽医院内科肿瘤学分科负责收集与留存维护。